search again

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Nationwide rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $512,861 · 10th–90th $0$1,174,8980%20%40%10th90th$512,861Professionalmedian $489,779 · 10th–90th $457,088$602,5600%50%10th90th$489,779$0.0$0.5$10.0$200.0$5.0K$100.0K$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$758,577.58
Typical High
$1,380,384.26
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
BCBS
Setting
Facility
Modifier
Global
Typical Low
$0.02
Median
$0.03
Typical High
$575,439.94
BCBS
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$616,595.00
Cigna
Setting
Facility
Modifier
Global
Typical Low
$676,082.98
Median
$1,258,925.41
Typical High
$1,513,561.25
Cigna
Setting
Professional
Modifier
Global
Typical Low
$457,088.19
Median
$537,031.80
Typical High
$588,843.66
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$812,830.52
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$467,735.14
Typical High
$851,138.04